Effect of a CD28H agonistic monoclonal antibody on NK cells

Mature NK cell activation relies on a balance of activating, co-stimulatory and inhibitory receptors involved during target recognition. Immunotherapy strategies has been developed to finely tune this balance in order to enhance NK cell cytotoxic functions against cancer cells and secretory functions to enhance adaptative immunity activation. CD28H, a new member of the CD28 family, has been recently studied in T cells and on NK cells as a part of CD28H-CAR-NKL strategy. Given the impressive expression of CD28H molecule on circulating NK cells, we evaluated the use an anti-CD28H mAb on NK cell activation. Overall design: RNAseq was performed on NK cells incubated overnight with anti-CD28H or the isotype control or untreated, during sixteen hours.